Semaglutide Achieves $16.7B in H1 Sales, Securing Global Blockbuster Status; BeiGene Reports First-Half Net Profit of RMB 450 Million
BeOne
Developer of Molecular Targeted and Immune Anti-Tumor Drugs
Qyuns
Developer of Biologics for Autoimmune and Allergic Diseases
Hansoh Pharma
Pharmaceutical Research, Production, and Sales
Hengrui Pharma
Innovative and High-Quality Pharmaceutical Developer
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
Semaglutide sells well.
On August 6, Novo Nordisk released its financial report for the first half of 2025. In the first six months, Novo Nordisk's sales reached 154.944 billion Danish kroner, growing by 16% in Danish kroner terms and 18% in fixed currency terms. Operating profit increased by 29% in fixed currency terms, with net profit reaching 55.537 billion Danish kroner.
Semaglutide's sales in the first half of the year reached 112.756 billion Danish kroner, approximately $16.7 billion, surpassing Keytruda. Specifically, the sales of Ozempic (semaglutide injection for diabetes) were 64.520 billion Danish kroner, while Wegovy (semaglutide injection for weight loss) reached 36.888 billion Danish kroner. Novo Nordisk has submitted a registration application to the European Medicines Agency for a higher dose of Wegovy (semaglutide 7.2 mg). Novo Nordisk stated that it will continue to increase commercial investment and promote the market penetration of Wegovy and Ozempic in more global markets.
BeOne Medicines Turns Profitable
On August 6, BeOne Medicines announced that the company's total operating revenue in the first half of 2025 was RMB 17.518 billion, representing a year-on-year increase of 46.0%; product revenue amounted to RMB 17.360 billion, marking a year-on-year increase of 45.8%; net profit attributable to the parent company’s owners reached RMB 450 million, compared with a loss of RMB 2.877 billion in the same period last year, turning losses into gains year on year.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Quanxin Biotech Receives 58 Million Yuan Milestone Payment
Recently, QX004N / HS-20137, jointly developed by Quanxin Biotech and Hansoh Pharma, has entered the Phase III clinical trial stage for psoriasis (Psoriasis, Ps), becoming the fourth product in Quanxin Biotech's pipeline to successfully advance to Phase III clinical trials. Quanxin Biotech announced that it has received milestone payments and other fees for the Ps Phase III trial from Hansoh Pharma under the licensing agreement, totaling RMB 58 million.
/ 02 /
Capital Information
1) BeOne Medicines' net profit in the first half of the year was 450 million yuan
On August 6, BeOne Medicines announced that its total operating revenue for the first half of 2025 reached 17.518 billion yuan, representing a year-on-year increase of 46.0%. Product revenue amounted to 17.360 billion yuan, marking a year-on-year rise of 45.8%. Net profit attributable to the parent company's owners was 450 million yuan, compared to a loss of 2.877 billion yuan in the same period last year, achieving a turnaround from loss to profit.
2) Beijing Tiantan Biological Products Corporation Limited's net profit for the first half of the year decreased by 12.88% year-on-year.
On August 6, Beijing Tiantan Biological Products Corporation Limited announced that its total operating revenue for the first half of 2025 was 3.11 billion yuan, representing a year-on-year increase of 9.47%; the net profit attributable to shareholders of the listed company was 633 million yuan, representing a year-on-year decrease of 12.88%.
/ 03 /
Pharmaceutical News
1) Hengrui Pharma's Recombinant Trastuzumab Granted FDA Orphan Drug Designation
On August 6, Hengrui Pharma announced that the injection of Recombinant Trastuzumab combined with Adebrelimab injection and chemotherapy for the treatment of gastric cancer or gastroesophageal junction adenocarcinoma has been granted Orphan Drug Designation by the US FDA.
2) Dizge Pharma's DZD8586 Granted FDA Fast Track Designation
On August 6, Dizhe Pharmaceuticals announced that its investigational product DZD8586 had been granted "Fast Track Designation" by the U.S. FDA for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in patients who have received at least two prior lines of therapy. DZD8586 is a first-in-class dual LYN/BTK inhibitor independently developed by the company, capable of simultaneously blocking both BTK-dependent and -independent BCR signaling pathways.
/ 04 /
Overseas Pharma News
1) In the first half of 2025, the sales of Semaglutide reached 16.7 billion US dollars, securing the top spot as the best-selling drug in advance.
On August 6, Novo Nordisk released its financial report for the first half of 2025. In the first six months, Novo Nordisk's sales reached 154.944 billion Danish kroner, increasing by 16% in Danish kroner terms and 18% in fixed currency terms, with operating profit growing by 29% in fixed currency terms. Net profit reached 55.537 billion Danish kroner. Sales of semaglutide in the first half of the year amounted to 112.756 billion Danish kroner, approximately 16.7 billion US dollars. Ozempic, the antidiabetic injectable version of semaglutide, achieved sales of 64.520 billion Danish kroner, while Wegovy, the weight-loss injectable version of semaglutide, generated 36.888 billion Danish kroner.
Novo Nordisk Submits Higher-Dose Wegovy (Semaglutide 7.2 mg) Registration Application to European Medicines Agency. Novo Nordisk States It Will Continue to Increase Commercial Investment and Promote Market Penetration of Wegovy and Ozempic in More Global Markets.
PS: Welcome to scan the QR code below to add Amino's WeChat for communication.
